Kenji Sugio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kenji Sugio has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Kosei Yasumoto
18 shared publicationsMitsuhiro Takenoyama
9 shared publications- Takeshi Hanagiri
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
9 shared publications - Hidetaka Uramoto
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
7 shared publications - Masakazu Sugaya
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Yahatanishi, Kitakyushu 807, Japan
7 shared publications - Tsunehiro Oyama
Imamitsu Homecare Clinic
6 shared publications
Latest Publications
- 1 June 2009
- Published by Elsevier in Lung Cancer
- Vol. 64 (3) , 314-318
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
- 1 June 2009
- Published by Elsevier in Lung Cancer
- Vol. 64 (3) , 314-318
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
- Open Access
Discrimination of multiple primary lung cancers from intrapulmonary metastasis based on the expression of four cancer‐related proteins
BACKGROUND: Because distinguishing between multiple primary lung cancers and intrapulmonary metastasis is often difficult when the tumor histology is same, the feasibility of analyzing differential protein expression profiles to distinguish multiple primary lung cancers from intrapulmonary metastasis was evaluated.METHODS: This study enrolled 50 patients, with multiple primary lung cancers demonstrating the same histology, who underwent surgery between April 1994 and March 2006 and 20 patients who were diagnosed to have intrapulmonary metastasis during the same period. Thirty patients with lymph‐node metastasis were selected for comparison purposes. The sum value of the differences in the expression ratio of 4 proteins (p53, p16, p27, and c‐erbB2) was evaluated in immunohistochemically stained specimens among multiple primary lung cancers and intrapulmonary metastasis.RESULTS: None of the 30 patients with lymph‐node metastasis showed a sum value of the differences between primary tumor and lymph‐node metastasis in the 4 protein expression ratios >90. Therefore, when the difference between 2 tumors exceeded 90, the 2 tumors were considered to be different from each other, ie, multiple primary lung cancers. Forty‐one of 50 (82%) patients who were clinically diagnosed to have multiple primary lung cancers showed a sum value of the differences in their protein expression ratios >90, 4 of 20 (20%) patients who were clinically diagnosed to have intrapulmonary metastasis showed a sum value >90. Among the patients who were clinically diagnosed to have multiple primary lung cancers and intrapulmonary metastasis, the 5‐year survival of 70 patients who had a sum value of the differences in their 4 protein expression ratios, either >90 (newly classified multiple primary lung cancers) and ≤90 (newly classified intrapulmonary metastasis), were 81.1% and 40.2%, respectively (P = .002).CONCLUSIONS: The profile of protein expression in cancer‐related genes is, thus, considered to be a useful tool for distinguishing multiple primary lung cancers from intrapulmonary metastasis and for determining the appropriate biological staging of lung cancer. Cancer 2009. © 2009 American Cancer Society.
Open AccessDiscrimination of multiple primary lung cancers from intrapulmonary metastasis based on the expression of four cancer‐related proteins
BACKGROUND: Because distinguishing between multiple primary lung cancers and intrapulmonary metastasis is often difficult when the tumor histology is same, the feasibility of analyzing differential protein expression profiles to distinguish multiple primary lung cancers from intrapulmonary metastasis was evaluated.METHODS: This study enrolled 50 patients, with multiple primary lung cancers demonstrating the same histology, who underwent surgery between April 1994 and March 2006 and 20 patients who were diagnosed to have intrapulmonary metastasis during the same period. Thirty patients with lymph‐node metastasis were selected for comparison purposes. The sum value of the differences in the expression ratio of 4 proteins (p53, p16, p27, and c‐erbB2) was evaluated in immunohistochemically stained specimens among multiple primary lung cancers and intrapulmonary metastasis.RESULTS: None of the 30 patients with lymph‐node metastasis showed a sum value of the differences between primary tumor and lymph‐node metastasis in the 4 protein expression ratios >90. Therefore, when the difference between 2 tumors exceeded 90, the 2 tumors were considered to be different from each other, ie, multiple primary lung cancers. Forty‐one of 50 (82%) patients who were clinically diagnosed to have multiple primary lung cancers showed a sum value of the differences in their protein expression ratios >90, 4 of 20 (20%) patients who were clinically diagnosed to have intrapulmonary metastasis showed a sum value >90. Among the patients who were clinically diagnosed to have multiple primary lung cancers and intrapulmonary metastasis, the 5‐year survival of 70 patients who had a sum value of the differences in their 4 protein expression ratios, either >90 (newly classified multiple primary lung cancers) and ≤90 (newly classified intrapulmonary metastasis), were 81.1% and 40.2%, respectively (P = .002).CONCLUSIONS: The profile of protein expression in cancer‐related genes is, thus, considered to be a useful tool for distinguishing multiple primary lung cancers from intrapulmonary metastasis and for determining the appropriate biological staging of lung cancer. Cancer 2009. © 2009 American Cancer Society.
- Open Access
- 2 April 2009
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 2 (3) , 353-357
Reduced expression of catenin subtypes is a potential indicator of unfavorable prognosis in esophageal squamous cell carcinoma
Catenins are cytoplasmic proteins that play a pivotal role in cell adhesion. Conflicting results regarding the significance of their expression in esophageal squamous cell carcinoma (ESCC) have been reported. The expression of α-, β- and γ-catenin was examined using immunohistochemical methods in 69 samples collected from patients with ESCC who were surgically treated without any preoperative induction therapy. Reduced α-, β- and γ-catenin expression was observed in 48 (69.7%), 36 (52.2%) and 44 (63.8%) ESCC samples, respectively. According to univariate analysis, ESCC patients exhibiting the reduced expression of β-catenin (P=0.028), γ-catenin (P=0.010), α- and γ-catenin combined (P=0.047) or β- and γ-catenin combined (P=0.046) had a significantly more unfavorable rate of survival. Multivariate analysis demonstrated that the reduced expression of γ-catenin (P=0.015) as well as lymph node metastasis (P=0.015) could serve as independent prognostic indicators of unfavorable prognosis in ESCC patients. Reduced immunohistochemical expression of γ-catenin may thus prove to be a powerfull and useful predictor of prognosis in patients with ESCC.
- 2 April 2009
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 2 (3) , 353-357
Open AccessReduced expression of catenin subtypes is a potential indicator of unfavorable prognosis in esophageal squamous cell carcinoma
Catenins are cytoplasmic proteins that play a pivotal role in cell adhesion. Conflicting results regarding the significance of their expression in esophageal squamous cell carcinoma (ESCC) have been reported. The expression of α-, β- and γ-catenin was examined using immunohistochemical methods in 69 samples collected from patients with ESCC who were surgically treated without any preoperative induction therapy. Reduced α-, β- and γ-catenin expression was observed in 48 (69.7%), 36 (52.2%) and 44 (63.8%) ESCC samples, respectively. According to univariate analysis, ESCC patients exhibiting the reduced expression of β-catenin (P=0.028), γ-catenin (P=0.010), α- and γ-catenin combined (P=0.047) or β- and γ-catenin combined (P=0.046) had a significantly more unfavorable rate of survival. Multivariate analysis demonstrated that the reduced expression of γ-catenin (P=0.015) as well as lymph node metastasis (P=0.015) could serve as independent prognostic indicators of unfavorable prognosis in ESCC patients. Reduced immunohistochemical expression of γ-catenin may thus prove to be a powerfull and useful predictor of prognosis in patients with ESCC.
- 12 June 2008
- Vol. 93 (1) , 50-4
Results of surgical treatment for lung cancer in young adults.
In this study, we evaluated the results of surgical treatment in young adults and compared the clinico-pathological features between young and elderly patients. We reviewed the clinical records of 1185 lung cancer patients who underwent surgery in our department. A total of 20 (1.7%) primary lung cancer patients (14 men and 6 women) < or =40 years of age were retrieved. The age range was from 26 to 40 years. Histological type included 10 adenocarcinomas (50%), 3 large cell carcinomas (15%), 3 carcinoids (15%), 2 squamous cell carcinomas (10%), and 2 others. The surgical procedure included 7 (35%) pneumonectomies, 11 (55.0%) lobectomies, and 1 (5%) partial resection. The proportion of pneumonectomies was significantly higher than among elderly patients. Clinical stage was underestimated in 7 of 20 patients, and among these, mediastinal lymph node metastases were revealed by pathological examination in 6 patients. Postoperative 5-year survival rates were 50.2%, 50.4%, and 43.8% in patients < or =40, 41-70, and > or =71 years old, respectively. There were no significant differences in survival rates between younger group and elderly groups. This study suggests that surgical resection is also recommended as the first-line treatment for younger patients with lung cancer.
- 12 June 2008
- Vol. 93 (1) , 50-4
Results of surgical treatment for lung cancer in young adults.
In this study, we evaluated the results of surgical treatment in young adults and compared the clinico-pathological features between young and elderly patients. We reviewed the clinical records of 1185 lung cancer patients who underwent surgery in our department. A total of 20 (1.7%) primary lung cancer patients (14 men and 6 women) < or =40 years of age were retrieved. The age range was from 26 to 40 years. Histological type included 10 adenocarcinomas (50%), 3 large cell carcinomas (15%), 3 carcinoids (15%), 2 squamous cell carcinomas (10%), and 2 others. The surgical procedure included 7 (35%) pneumonectomies, 11 (55.0%) lobectomies, and 1 (5%) partial resection. The proportion of pneumonectomies was significantly higher than among elderly patients. Clinical stage was underestimated in 7 of 20 patients, and among these, mediastinal lymph node metastases were revealed by pathological examination in 6 patients. Postoperative 5-year survival rates were 50.2%, 50.4%, and 43.8% in patients < or =40, 41-70, and > or =71 years old, respectively. There were no significant differences in survival rates between younger group and elderly groups. This study suggests that surgical resection is also recommended as the first-line treatment for younger patients with lung cancer.
- 1 January 2008
- Vol. 61 (1) , 37-42
[Molecular targeted therapy and tailor-made therapy for lung cancer].
Somatically acquired mutations in the epidermal growth factor receptor (EGFR) gene in lung cancer are associated with significant clinical responses to gefitinib, a tyrosine kinase inhibitor (TKI) that targets EGFR. In our previous report, 42.2% of adenocarcinoma patients has EGFR mutations, and these mutations were more frequently found in women than in men, in well differentiated tumors than poorly differentiated tumors, and in patients who were never smokers than in patients who were current/former smokers. Retrospectively, we screened the EGFR gene of tumors in 37 NSCLC patients who had been treated with gefitinib. EGFR mutations were found in 22 patients. Gefitinib was effective (CR/PR) in 15 of 22 (68.2%) patients with mutations compared with none of 15 patients without mutations. Patients with EGFR mutations survived for a longer period than without the mutations after initiation of gefitinib treatment (p = 0.0005). Gefitinib was not effective in 3 patients with K-ras mutations. Three of 4 tumors obtained from patients with acquired resistant to gefitinib, had a secondary T790M mutation. No T790M mutation was detected in pretreatment tumors. Molecular targeted therapy using TKI indicates an effective therapy specifically in lung cancer patients with EGFR mutations, and analyses of mechanisms of resistance to TKI are necessary for establishment of tailor-made therapy.
- 1 January 2008
- Vol. 61 (1) , 37-42
[Molecular targeted therapy and tailor-made therapy for lung cancer].
Somatically acquired mutations in the epidermal growth factor receptor (EGFR) gene in lung cancer are associated with significant clinical responses to gefitinib, a tyrosine kinase inhibitor (TKI) that targets EGFR. In our previous report, 42.2% of adenocarcinoma patients has EGFR mutations, and these mutations were more frequently found in women than in men, in well differentiated tumors than poorly differentiated tumors, and in patients who were never smokers than in patients who were current/former smokers. Retrospectively, we screened the EGFR gene of tumors in 37 NSCLC patients who had been treated with gefitinib. EGFR mutations were found in 22 patients. Gefitinib was effective (CR/PR) in 15 of 22 (68.2%) patients with mutations compared with none of 15 patients without mutations. Patients with EGFR mutations survived for a longer period than without the mutations after initiation of gefitinib treatment (p = 0.0005). Gefitinib was not effective in 3 patients with K-ras mutations. Three of 4 tumors obtained from patients with acquired resistant to gefitinib, had a secondary T790M mutation. No T790M mutation was detected in pretreatment tumors. Molecular targeted therapy using TKI indicates an effective therapy specifically in lung cancer patients with EGFR mutations, and analyses of mechanisms of resistance to TKI are necessary for establishment of tailor-made therapy.
- Open Access
- 1 January 2008
- Published by National Library of Serbia in Archive of Oncology
- Vol. 16 (3-4) , 77-80
Marked clinical and immunological response of MAGE-A3 peptides vaccination in a patient with adenocarcinoma of the lung case report: A case report
A 56-year patient was diagnosed adenocarcinoma of the right lung and underwent lower lobectomy. Pleural dissemination was observed, and the pathological stage was T4N0M0. Systemic chemotherapy was performed with paclitaxel and vinorelbine after the surgery. Because multiple pulmonary and liver metastases were appeared 1 year after the surgery, the second line chemotherapy (CDDP and 5FU) was performed. The response of the chemotherapy was not observed, and thus the patient was enrolled in the clinical trial of MAGE-A3 peptide vaccine with OK-432. The peptide (300 mg) was injected subcutaneously at the upper thigh or upper arm a total of 6 times over 2 months (days 1, 8, 15, 22, 36, and 50) with OK432. During two courses of the vaccinations, the tumor markers (CA19-9 and CEA) decreased markedly. Furthermore, the tumor size of the lung and liver metastases decreased to 30% of their pre-treatment size. The delayed type hypersensitive reaction became positive after the first course of vaccinations. The precursor CTL for the peptide in the peripheral blood had increased after the vaccination. MAGE-A3 peptide vaccination with OK-432 has a potential to induce immunological response and clinical response in advanced lung cancer patients.
- 1 January 2008
- Published by National Library of Serbia in Archive of Oncology
- Vol. 16 (3-4) , 77-80
Open AccessMarked clinical and immunological response of MAGE-A3 peptides vaccination in a patient with adenocarcinoma of the lung case report: A case report
A 56-year patient was diagnosed adenocarcinoma of the right lung and underwent lower lobectomy. Pleural dissemination was observed, and the pathological stage was T4N0M0. Systemic chemotherapy was performed with paclitaxel and vinorelbine after the surgery. Because multiple pulmonary and liver metastases were appeared 1 year after the surgery, the second line chemotherapy (CDDP and 5FU) was performed. The response of the chemotherapy was not observed, and thus the patient was enrolled in the clinical trial of MAGE-A3 peptide vaccine with OK-432. The peptide (300 mg) was injected subcutaneously at the upper thigh or upper arm a total of 6 times over 2 months (days 1, 8, 15, 22, 36, and 50) with OK432. During two courses of the vaccinations, the tumor markers (CA19-9 and CEA) decreased markedly. Furthermore, the tumor size of the lung and liver metastases decreased to 30% of their pre-treatment size. The delayed type hypersensitive reaction became positive after the first course of vaccinations. The precursor CTL for the peptide in the peripheral blood had increased after the vaccination. MAGE-A3 peptide vaccination with OK-432 has a potential to induce immunological response and clinical response in advanced lung cancer patients.
- 19 August 2007
- Vol. 27, 2297-303
A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR.
Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.
- 19 August 2007
- Vol. 27, 2297-303
A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR.
Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.
- 1 August 2007
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S509-S510
P2-049: Cytochrome P450 expression in non-small cell lung cancer
- 1 August 2007
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S509-S510
P2-049: Cytochrome P450 expression in non-small cell lung cancer
- 1 August 2007
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S696
P2-310: Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer
- 1 August 2007
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (8) , S696
P2-310: Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer
- 1 April 2007
- Vol. 34 (4) , 538-43
[Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations].
EGFR-TKI has been synthesized as a potential target for cancer therapy because EGFR is overexpressed and associated with poor prognosis of lung cancer. It was reported that EGFR mutations were more sensitive to EGFRTKI than those without the mutations among lung cancer patients. A subgroup of patients of Asian origin, female sex, adenocarcinoma, and no history of smoking were significantly associated with a high rate of EGFR mutations. These patients with EGFR mutations were not only favorable responders but also had a longer survival than without. In this article, we discuss the EGFR-TKI predictive factors by EGFR mutations.
- 1 April 2007
- Vol. 34 (4) , 538-43
[Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations].
EGFR-TKI has been synthesized as a potential target for cancer therapy because EGFR is overexpressed and associated with poor prognosis of lung cancer. It was reported that EGFR mutations were more sensitive to EGFRTKI than those without the mutations among lung cancer patients. A subgroup of patients of Asian origin, female sex, adenocarcinoma, and no history of smoking were significantly associated with a high rate of EGFR mutations. These patients with EGFR mutations were not only favorable responders but also had a longer survival than without. In this article, we discuss the EGFR-TKI predictive factors by EGFR mutations.